瑞舒伐他汀与阿托伐他汀治疗冠心病的效果比较

Comparison of the effect of rosuvastatin and atorvastatin in the treatment of coronary heart disease

目的比较瑞舒伐他汀与阿托伐他汀治疗冠心病的临床效果。方法选择2019年1月—2020年9月甘肃省白银市第一人民医院收治的冠心病患者168例,以随机数字表法分为瑞舒伐他汀组与阿托伐他汀组,每组84例。2组患者均给予常规心内科治疗,在此基础上,瑞舒伐他汀组患者应用瑞舒伐他汀治疗,阿托伐他汀组患者应用阿托伐他汀治疗,2组患者均连续治疗6个月。比较2组治疗效果,治疗前后心功能[左室射血分数(LVEF)、血管舒张功能(FMD)]、血脂[总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、炎性因子[血清超敏C反应蛋白(hs-CRP)、白介素-35(IL-35)和核因子-κB(NF-κB)]水平及不良反应。结果治疗6个月后,瑞舒伐他汀组的总有效率为95.24%,高于阿托伐他汀组的85.71%(χ^(2)=4.421,P=0.035)。治疗6个月后,2组患者LVEF和FMD均高于治疗前,且瑞舒伐他汀组患者高于阿托伐他汀组(P<0.01);2组患者TC、TG、LDL-C、hs-CRP和NF-κB水平均低于治疗前,HDL-C及IL-35水平均高于治疗前,且瑞舒伐他汀组患者降低/升高幅度大于阿托伐他汀组(P<0.01)。瑞舒伐他汀组患者不良反应总发生率为8.33%,阿托伐他汀组患者不良反应总发生率为7.14%,2组比较差异无统计学意义(χ^(2)=0.083,P=0.773)。结论瑞舒伐他汀治疗冠心病的综合疗效优于阿托伐他汀,更有助于调节血脂水平,控制炎性反应,促进患者心功能改善,且用药安全性较高,值得临床推广应用。

Objective To compare the clinical effects of rosuvastatin and atorvastatin in the treatment of coronary heart disease.Methods 168 patients with coronary heart disease admitted to the the 1st People's Hospital of Baiyin,Gansu Province from January 2019 to September 2020 were selected,they were divided into rosuvastatin group and atorvastatin group by random number table method,with 84 cases in each group.Both groups were given routine cardiology treatment,on this basis,the patients in the rosuvastatin group were treated with rosuvastatin,the patients in the atorvastatin group were treated with atorvastatin,and the patients in both groups were treated for 6 months.Compared the treatment effects,cardiac function[left ventricular ejection fraction(LVEF),vasodilation(FMD)],blood lipids[total cholesterol(TC),triglyceride(TG),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C)]and inflammatory factors[serum high-sensitivity C-reactive protein(hs-CRP),interleukin-35(IL-35)and nuclear factor-κB(NF-κB)]levels,adverse reactions before and after treatment of the two groups.Results After 6 months of treatment,the total effective rate in the rosuvastatin group was 95.24%,which was higher than 85.71% in the atorvastatin group(χ^(2)=4.421,P=0.035).After 6 months of treatment,the LVEF and FMD of the two groups were higher than those before treatment,and the patients in the rosuvastatin group were higher than those in the atorvastatin group(P<0.01);The levels of TC,TG,LDL-C,hs-CRP and NF-κB in the two groups were lower than those before treatment,while the levels of HDL-C and IL-35 were higher than those before treatment,and the rosuvastatin group decreased/increase was greater than that in the atorvastatin group(P<0.01).The total incidence of adverse reactions in the rosuvastatin group was 8.33%,and the total incidence of adverse reactions in the atorvastatin group was 7.14%,with no significant difference between the two groups(χ^(2)=0.083,P=0.773).Conclusion The comprehensive efficacy of rosuvastatin in the treatment of coronary heart disease is better than that of atorvastatin,and it is more helpful to regulate blood lipid levels,control inflammatory response,and promote the improvement of patients'heart function.